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OBJECTIVE— The aim of this study was to compare pregnancy outcomes in type 1 diabetic
pregnancies with the background population.
RESEARCH DESIGN AND METHODS— This nationwide prospective multicenter
study took place in eight Danish centers treating pregnant women with type 1 diabetes during
1993–1999. A total of 990 women with 1,218 pregnancies and delivery after 24 weeks (n 
1,215) or early termination due to severe congenital malformations (n 3) were included. Data
were collected prospectively by one to three caregivers in each center and reported to a central
registry.
RESULTS— The perinatal mortality rate was 3.1% in type 1 diabetic pregnancies compared
with 0.75% in the background population (RR 4.1 [95% CI 2.9–5.6]), and the stillbirth rate was
2.1% compared with 0.45 (4.7 [3.2–7.0]). The congenital malformation rate was 5.0% in the
study population and 2.8% (1.7 [1.3–2.2]) in the background population. Six of the perinatal
deaths (16%) were related to congenital malformations. Only 34% of women performed daily
home monitoring of blood glucose at conception, and 58% received preconceptional guidance.
Pregnancies with serious adverse outcomes (perinatal death and/or congenital malformations)
were characterized by higher HbA1c values before and during pregnancy and a lesser degree of
maternal self-care and preconceptional guidance. Women who performed daily self-monitoring
of blood glucose at any time during pregnancy had lower HbA1c values than women who did not
measure their daily profile. Likewise, daily self-monitoring was associated with a reduction in
serious adverse outcomes. The caesarean section rate was 55.9 and 12.6%, respectively, and the
risk of preterm delivery was 41.7 and 6.0%, respectively.
CONCLUSIONS— Type 1 diabetic pregnancies are still complicated by considerably higher
rates of severe perinatal complications compared with the background population, and women
with poor self-care are at the highest risk. Adequate glycemic control using daily glucose mon-
itoring before and during pregnancy is a crucial step toward reaching the goals of the St. Vincent
declaration.
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In 1989, the St. Vincent declaration (1)stated that the outcome of diabeticpregnancy should approximate that of
the nondiabetic pregnancy within 5 years.
Since then, four regional prospective
studies from the U.K. and Finland (2–5)
and two nationwide studies from Holland
and France (6,7) have reported rates for
perinatal mortality and/or congenital mal-
formations, considerably higher than the
background population. The number of
pregnancies varied from 111 to 691. In
Denmark, clinical data have been pro-
spectively collected since 1992, which
enables us to analyze data on a cohort of
1,200 consecutive pregnancies. The ob-
jective was to compare pregnancy out-
comes in type 1 diabetic pregnancies with
the background population.
RESEARCH DESIGN AND
METHODS— During 1993–1999, all
pregnancies in women with pregesta-
tional type 1 diabetes were prospectively
reported to a central registry in the Danish
Diabetes Association. The patients deliv-
ered in eight centers: four university hos-
pitals (Copenhagen, Aarhus, Aalborg,
and Odense) and four county hospitals
(Esbjerg, Fredericia, Herning, and Hill-
erød) with special interest in diabetes and
pregnancy. Information of maternal de-
mography, diabetes status, and preg-
nancy outcome were collected after each
delivery by one to three caregivers per
center. All patients gave informed con-
sent, and the local ethic committees ap-
proved the study. Inclusion criteria were
delivery after 24 completed weeks (n 
1,215) or termination before 24 weeks be-
cause of ultrasound-verified severe malfor-
mation (n 3). Abortions before 24 weeks
for other reasons were not registered.
Local assays for HbA1c were used.
Correction was made to a common stan-
dard (normal range of standard assay,
0.044–0.064) by multiplying the HbA1c
value with a correction factor (mean of the
reference values for a standard assay di-
vided by the mean of the reference values
for the given assay). The assays for HbA1c
were subjected to thorough quality con-
trol during this period. The coverage of
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the reporting of cases from the centers
was 75–93% evaluated by alternative lo-
cal data sources. In one region (Northern
Jutland County), data were cross-checked
with a hospital discharge registry and an
insulin-prescription registry, yielding a
coverage of 75%. In the Odense Univer-
sity Hospital area, local registration of
pregnant women with diabetes (type 1,
type 2, and gestational diabetes) was per-
formed by the head of the obstetric de-
partment, and 93% of women with type 1
diabetes were found in both registries.
Maternal characteristics and pregnancy
outcome showed no differential selection,
suggesting that the results from the regis-
try can be generalized despite incomplete
data ascertainment. No significant varia-
tion in data collection was present over
the years. Data on the background popu-
lation were based on 70,089 deliveries re-
corded by the Danish Health Board in
1995 (8). Statistics were performed with
STATA 7.0 (Stata Corporation, College
Station, TX). Data are given as standard
deviation and mean, median and inter-
quartile range, or numbers and percent.
Mann-Whitney U test or 2 test was used
for comparing pregnancies with and
without serious outcomes. Logistic re-
gression analysis was performed to deter-
mine predictors for perinatal mortality
and/or congenital malformations. P val-
ues 0.05 were considered statistically
significant.
Perinatal mortality was defined as
stillbirth (intrauterine death after 24
weeks of gestation) or death during the
first 7 days of life. Congenital malforma-
tions were assessed during hospital stay,
whereas malformations diagnosed on a
subsequent examination were not regis-
tered. Major congenital malformations
were those responsible for death, causing
a significant future handicap, or requiring
major surgery, whereas minor congenital
malformations comprise the remainder
(9). Macrosomia was defined as birth
weight 4,500 g or birth weight 90th
percentile for a Danish standard popula-
tion (10), and preterm delivery was delivery
before 37 completed weeks. Preeclampsia
was defined as blood pressure 140/90
mmHg and proteinuria 2 on a urine pro-
tein test strip (equal to 1.0 g/l).
RESULTS— Data were reported on
1,218 consecutive pregnancies in 990
women during the study period. Twenty-
eight were twin pregnancies. Patients had
a mean age of 28.8 years and mean BMI of
22.9 kg/m2 (not different from the back-
ground population), duration of diabetes
was 12 years (5–19), and the time for ad-
mission to the center was 9 gestational
weeks (8–11) (median and interquartile
range). Information of preconceptional
guidance was recorded in 1,153 women,
and 669 (58%) had received guidance. At
the time of admission, 381 (34%) per-
formed daily blood glucose monitoring,
whereas 53, 62, and 65% did that in the
first, second, and third trimester. HbA1c
values decreased with advancing preg-
nancy: 0 –3 months before conception
(7.6% [6.8–8.6]); first trimester (7.3%
[6.6–8.2]); second trimester (6.6% [6.0–
8.3]); and third trimester (6.7% [6.2–
7.4]) (median and interquartile range).
Approximately 95% of the women were
treated with insulin four times a day (bas-
al/bolus regime) before and during preg-
nancy. None of the women used insulin
pumps.
Obstetric and fetal characteristics for
patients and the reference population are
shown in Table 1. Infants of women with
type 1 diabetes were delivered earlier, and
rates of caesarean section, macrosomia,
stillbirth, perinatal mortality, and con-
genital malformations were higher than in
normal newborns. Thirty-two (52%) of
the detected congenital malformations
were defined as major.
Among the 680 caesarean sections,
373 (55%) were performed electively. A
total of 255 (48%) of the preterm deliver-
ies were based on obstetrical or medical in-
dications and followed by either induction
of labor or elective caesarean section. Eigh-
teen percent had preeclampsia versus 2.6%
in the background population (data from
the National Danish Patient Registry 1998–
2000, Marianne Johansen, personal com-
munication, Copenhagen).
Table 2 gives maternal characteristics
in pregnancies with and without serious
adverse outcomes (perinatal mortality
and/or congenital malformations). Ad-
verse outcomes were associated with sig-
nificantly higher HbA1c values before and
during pregnancy and with lower rates of
preconceptional guidance and daily
blood glucose monitoring before concep-
tion. Mothers with severe adverse out-
comes had lower preconceptional BMI.
The congenital malformations affected
Table 1—Obstetric complications and fetal characteristics for type 1 diabetic pregnancies and the background population
Type 1 diabetic pregnancy Background population RR (95% CI) or P
n 1,215 70,089
Pre-eclampsia* 220 (18.1%) * 0.001
Caesarean section 680 (55.9%) 8,831 (12.6%) 4.4 (4.1–4.8)
Preterm delivery† 507 (41.7%) 4,205 (6.0%) 7.0 (6.3–7.6)
Gestational age at delivery (days) 256  16 280 0.0001
Birth weight (g) 3,487  817 3,478 0.71
Birth weight 4,500 g 97 (8.0%) 2,383 (3.4%) 2.3 (1.9–2.9)
Large for gestational age infant‡ 761 (62.5%) — 0.001
Stillbirth 26 (2.1%) 318 (0.45%) 4.7 (3.2–7.0)
Perinatal mortality 38 (3.1%) 525 (0.75%) 4.1 (2.9–5.6)
Congenital malformations 61 (5.0%) 1,987 (2.8%) 1.7 (1.3–2.2)
Respiratory distress syndrome§ 202 (17.1%) ND —
Jaundice 215 (18.1%) ND —
Data are means SD or n (%). *Blood pressure140/90 mmHg and proteinuria. The frequency in the background population is 2.6% (other data source, see text);
†before 37 completed weeks of gestation; ‡birth weight 90th centile. The expected frequency in the background population is 10%, but exact numbers are not
available; §use of continuous positive airway pressure for 1 h postpartum; use of phototherapy. ND, no data.
Type 1 diabetic pregnancies
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the following organ systems: 44% cardio-
vascular, 18% musculoskeletal, 13% uri-
nary, 7% central nervous, and 18%
others. The neonatal deaths were primar-
ily associated with preterm delivery (30.0
weeks [26.5–33.1] median [interquartile
range]); 3 of the 12 infants had major con-
genital malformations. Logistic regression
analysis was performed entering only data
from the first pregnancy for each woman
in the study (index pregnancy, n 990).
In univariate analysis, significant predic-
tors (P  0.05) for serious adverse out-
comes were absence of daily monitoring
of blood glucose before conception (P 
0.023), HbA1c 0–3 months before con-
ception (P  0.029), second trimester
HbA1c (0.043), and third trimester HbA1c
(P  0.01). Absence of preconceptional
guidance and first trimester HbA1c tended
to be associated with perinatal mortality/
congenital malformations (P 0.062 and
P  0.13, respectively). When entering
the four HbA1c values one at a time in a
multivariate model with preconceptional
guidance and daily blood glucose moni-
toring, only third-trimester HbA1c re-
mained significantly associated with
serious adverse outcome.
Women who performed daily blood
glucose self-monitoring at any time dur-
ing pregnancy had lower HbA1c values
(mean  SD) than women who did not
measure daily: preconceptional HbA1c
7.2  1.1 vs. 7.8  1.5% (P  0.0001);
second trimester HbA1c 6.7  1.0% vs.
7.1  1.2% (P  0.0001); and third tri-
mester HbA1c 6.7  0.9 vs. 7.1  1.1%
(P  0.0001). Likewise, daily self-
monitoring was negatively associated
with serious adverse outcomes in univar-
iate analyses: preconceptional 4.6 vs.
7.6% (P  0.03); first trimester 5.3 vs.
8.3% (P  0.037); second trimester 5.7
vs. 8.3% (P 0.087); and third trimester
5.3 vs. 8.1% (P  0.061).
CONCLUSIONS— To our knowl-
edge, this is the largest prospective popu-
lation-based study of unselected pregnant
women with type 1 diabetes. It could be
argued that a number of women might
have type 2 diabetes, as no data were re-
corded on C-peptide or islet cell immune
markers. However, women entering the
study were all judged as having type 1
diabetes by their caretakers and were on
insulin treatment before conception, the
majority were normal weight, and the
mean diabetes duration was 12 years.
As in other series from the 1990s (2–
7,11,12), we found increased rates of ob-
stetric complications, stillbirth, perinatal
mortality, congenital malformations, and
macrosomia compared with the back-
ground population. There was a striking
increased risk for preterm delivery (more
than one-half of them spontaneous),
which is an important risk factor for in-
fant morbidity.
The stillbirth rate in our study (2.1%)
was comparable with the rate of 1.9% in
Scotland (5) and 2.0% in Newcastle-
upon-Tyne, U.K. (3). Perinatal mortality
was 3.1%, which was also in the same
magnitude as in the national studies from
Holland and Scotland (5,6) (3.2 and
2.8%, respectively). In two consecutive co-
horts in the Liverpool area, U.K. (2,11), and
in one cohort from Newcastle-upon-Tyne
(3), perinatal mortality tended to be higher
(3.6–4.3 and 4.8%, respectively), but the
difference was not statistically significant.
The congenital malformation rates
differed substantially, with frequencies of
7.9–9.7% in the studies from Holland
and England and rates of 4.2–6.1% in the
Scandinavian and Scottish series. The rel-
ative risk for congenital malformations in
the present study was lower: 1.7 among
offspring of diabetic women compared
with offspring of normal women. Malfor-
mations were assessed during the first
week of life in offspring of diabetic moth-
ers, whereas congenital malformations in
the background population were re-
ported to a central registry after the first
year of life. This would tend to underesti-
mate both the congenital malformation rate
in diabetic women and the relative risk
compared with the background popula-
tion. In contrast to most previous studies,
we also included pregnancies terminated
before 24 weeks due to ultrasound-
diagnosed congenital malformations.
For decades, management of preg-
nant women with diabetes has focused on
the importance of optimizing glycemic
Table 2—Maternal characteristics in pregnancies with serious adverse outcomes (perinatal death and/or congenital malformations) versus
other pregnancies
Serious adverse outcome Others P
n 93 1,125
Age (years) 28 (25–31) 29 (26–32) 0.49
Preconceptional BMI (kg/m2) 22.1 (19.4–24.2) 23.0 (21.4–25.3) 0.01
Diabetes duration (years) 12 (6–18) 12 (5–19) 0.75
Daily blood glucose monitoring at conception 18 (22.5%) 363 (34.6%) 0.019
Preconceptional guidance 38 (42.7%) 631 (59.2%) 0.002
HbA1c 0–3 months prior to conception (%) 8.0 (7.3–9.1) 7.6 (6.8–8.5) 0.005
HbA1c during first trimester (%) 7.6 (6.6–8.6) 7.3 (6.6–8.1) 0.037
HbA1c during second trimester (%) 6.9 (6.2–8.0) 6.6 (6.0–7.3) 0.012
HbA1c during third trimester (%) 7.1 (6.5–7.9) 6.7 (6.2–7.4) 0.001
Retinopathy* 5 (5.8%) 78 (7.3%) 0.58
Nephropathy† 8 (9.0%) 70 (6.4%) 0.34
Hypertension‡ 6 (6.7%) 53 (4.8%) 0.45
Pre-eclampsia§ 15 (18.1%) 205 (18.1%) 1.0
Large for gestational age infant 48 (57.1%) 713 (62.9%) 0.30
Data are median (interquartile range) or n (%). For some of the variables, the total number is1,218 due to missing values. *Proliferative retinopathy; †nephropathy
(urine albumin excretion 300 mg/24 h or 200 g/min); ‡hypertension (pharmacological treatment) before pregnancy and/or during first trimester; §blood
pressure 140/90 mmHg and proteinuria; birth weight 90th centile.
Jensen and Associates
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control before and during pregnancy. In
Denmark, health care is free with equal
access for all citizens, and young women
with diabetes are offered regular visits to
diabetologists. Therefore, it was disappoint-
ing that only one-third of the women per-
formed daily home glucose monitoring at
the time of conception and that nearly one-
half of them did not receive prepregnancy
guidance. Moreover, our study clearly un-
derlines that women using home blood glu-
cose monitoring had better glycemic
control throughout pregnancy as well as a
better pregnancy outcome.
HbA1c is a crude measure of glucose
control during pregnancy, as it reflects
changes in glucose over several weeks,
and therefore results of glucose profiles
during home monitoring might have
added important information. Unfortu-
nately, these data were not reported to the
central registry. The clinical decisions
during pregnancy were, of course, also
based on glucose profiles and not only on
HbA1c values.
Our study confirms that poor meta-
bolic control before and during preg-
nancy is associated with perinatal
mortality and congenital malformations.
Furthermore, these outcomes were pre-
dated by inadequate maternal self-care
(home monitoring of blood glucose) and
professional care (preconceptional guid-
ance). Finally, women with adverse preg-
nancy outcome seemed to have slightly
more hypertension and overt diabetic ne-
phropathy at conception, but this did not
reach statistical significance. In the multi-
variate analysis, only third-trimester
HbA1c remained a significant predictor.
However, as perinatal mortality and con-
genital malformations are rare complica-
tions, sufficient statistical power would
require an even larger study population.
HbA1c level decreased during preg-
nancy but was still higher than the refer-
ence interval for individuals without
diabetes. This decrease might be due to
the intensified insulin regimen; however,
recent Danish investigations have shown
that HbA1c values also decrease during
pregnancy in normal women and that
third-trimester reference interval is as low
as 4.4–5.6% (13). Thus, many of our pa-
tients were far from optimally controlled,
and consequently, we should aim at even
tighter glycemic control. However, the
price could be more hypoglycemic epi-
sodes. As shown by Evers et al. (14), the
risk is increased during early pregnancy
and in women with a history of severe
hypoglycemia, high daily insulin dose,
and long duration of diabetes. With this
knowledge and an increased patient com-
pliance with respect to home blood glu-
cose measuring, it should be possible to
tailor individual treatment regimens.
Like other investigators, we found an
increased risk of macrosomia, despite ear-
lier delivery in women with type 1 diabe-
tes. In the Dutch population (15), one-
half of the diabetic women delivered
macrosomic infants (birth weight 90th
percentile) with a mean third-trimester
HbA1c in this group of 6.4% (normal non-
pregnant reference value 4.0–6.0%). The
authors concluded that macrosomia oc-
curred despite apparent good glycemic
control. According to the above-
mentioned reference intervals for normal
pregnant women, it could be argued that
this is far from normal physiologic glu-
cose levels.
The goals of the St. Vincent declara-
tion have not yet been obtained. A nation-
wide Swedish study (1983–1985)
reported congenital malformation rates
similar to the general population and
moderately increased risk of macrosomia
in diabetic women (16), whereas data
from the Swedish Medical Birth Registry
(1991–1996) showed an increase in mac-
rosomia and a threefold risk of congenital
malformations in diabetic women (12).
An audit from Northern Ireland reported
data from 978 pregnancies in diabetic
mothers during 1985–1995 (17). Perina-
tal mortality rates were higher in women
who were managed in a local maternity
unit compared with a regional center (3.6
vs. 2.9%). Women who registered for pre-
natal care locally and were transferred to
the regional center midpregnancy had a
much higher perinatal mortality of 7.5%.
The results underline the importance of
centralization and early referral of pregnant
women with diabetes. Analyses of uns-
elected populations are necessary to set re-
alistic goals for pregnancy outcome, as
single-center studies from highly special-
ized hospitals tend to be overly optimistic.
In accordance with the Swedish data,
the study from Northern Ireland did not
demonstrate any improvements in preg-
nancy outcome over time. The reason for
this is not clear. It could be speculated
that more diabetic women with complica-
tions become pregnant due to improved
treatment of infertility. Furthermore, the
maternal age of the first pregnancy is in-
creasing (8), which is a fact that might
have more severe implications for women
with diabetes.
Our data suggest that glycemic con-
trol, self-care, and education of the patient
still need to be improved significantly and
that adequate control using daily glucose
monitoring in all patients is a crucial step
toward reaching the goals of the St. Vin-
cent Declaration. Future research should
focus on tools for better preconceptional
care, development of new methods like
continuous glucose monitoring, more ef-
ficient insulin regimens, and assessment
of risk indicators for certain adverse out-
comes. This would make it possible to in-
dividualize treatment and target health
care resources to risk groups.
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